Cargando…

Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic

The COVID-19 pandemic has unleashed a deluge of publications. For this cross-sectional study we compared the amount and reporting characteristics of COVID-19-related academic articles and preprints and the number of ongoing clinical trials and systematic reviews. To do this, we searched the PubMed d...

Descripción completa

Detalles Bibliográficos
Autores principales: Gianola, Silvia, Jesus, Tiago S., Bargeri, Silvia, Castellini, Greta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537872/
https://www.ncbi.nlm.nih.gov/pubmed/33022014
http://dx.doi.org/10.1371/journal.pone.0240123
_version_ 1783590751639175168
author Gianola, Silvia
Jesus, Tiago S.
Bargeri, Silvia
Castellini, Greta
author_facet Gianola, Silvia
Jesus, Tiago S.
Bargeri, Silvia
Castellini, Greta
author_sort Gianola, Silvia
collection PubMed
description The COVID-19 pandemic has unleashed a deluge of publications. For this cross-sectional study we compared the amount and reporting characteristics of COVID-19-related academic articles and preprints and the number of ongoing clinical trials and systematic reviews. To do this, we searched the PubMed database of citations and abstracts for published life science journals by using appropriate combinations of medical subject headings (MeSH terms), and the COVID-19 section of the MedRxiv and BioRxiv archives up to 20 May 2020 (21 weeks). In addition, we searched Clinicaltrial.gov, Chinese Clinical Trial Registry, EU Clinical Trials Register, and 15 other trial registers, as well as PROSPERO, the international prospective register of systematic reviews. The characteristics of each publication were extracted. Regression analyses and Z tests were used to detect publication trends and their relative proportions. A total of 3635 academic publications and 3805 preprints were retrieved. Only 8.6% (n = 329) of the preprints were already published in indexed journals. The number of academic and preprint publications increased significantly over time (p<0.001). Case reports (6% academic vs 0.9% preprints; p<0.001) and letters (17.4% academic vs 0.5% preprints; p<0.001) accounted for a greater share of academic compared to preprint publications. Differently, randomized controlled trials (0.22% vs 0.63%; p<0.001) and systematic reviews (0.08% vs 5%) made up a greater share of the preprints. The relative proportion of clinical studies registered at Clinicaltrials.gov, Chinese Clinical Trial Registry, and EU Clinical Trials Register was 57.9%, 49.5%, and 98.9%, respectively, most of which were still “recruiting”. PROSPERO listed 962 systematic review protocols. Preprints were slightly more prevalent than academic articles but both were increasing in number. The void left by the lack of primary studies was filled by an outpour of immediate opinions (i.e., letters to the editor) published in PubMed-indexed journals. Summarizing, preprints have gained traction as a publishing response to the demand for prompt access to empirical, albeit not peer-reviewed, findings during the present pandemic.
format Online
Article
Text
id pubmed-7537872
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-75378722020-10-15 Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic Gianola, Silvia Jesus, Tiago S. Bargeri, Silvia Castellini, Greta PLoS One Research Article The COVID-19 pandemic has unleashed a deluge of publications. For this cross-sectional study we compared the amount and reporting characteristics of COVID-19-related academic articles and preprints and the number of ongoing clinical trials and systematic reviews. To do this, we searched the PubMed database of citations and abstracts for published life science journals by using appropriate combinations of medical subject headings (MeSH terms), and the COVID-19 section of the MedRxiv and BioRxiv archives up to 20 May 2020 (21 weeks). In addition, we searched Clinicaltrial.gov, Chinese Clinical Trial Registry, EU Clinical Trials Register, and 15 other trial registers, as well as PROSPERO, the international prospective register of systematic reviews. The characteristics of each publication were extracted. Regression analyses and Z tests were used to detect publication trends and their relative proportions. A total of 3635 academic publications and 3805 preprints were retrieved. Only 8.6% (n = 329) of the preprints were already published in indexed journals. The number of academic and preprint publications increased significantly over time (p<0.001). Case reports (6% academic vs 0.9% preprints; p<0.001) and letters (17.4% academic vs 0.5% preprints; p<0.001) accounted for a greater share of academic compared to preprint publications. Differently, randomized controlled trials (0.22% vs 0.63%; p<0.001) and systematic reviews (0.08% vs 5%) made up a greater share of the preprints. The relative proportion of clinical studies registered at Clinicaltrials.gov, Chinese Clinical Trial Registry, and EU Clinical Trials Register was 57.9%, 49.5%, and 98.9%, respectively, most of which were still “recruiting”. PROSPERO listed 962 systematic review protocols. Preprints were slightly more prevalent than academic articles but both were increasing in number. The void left by the lack of primary studies was filled by an outpour of immediate opinions (i.e., letters to the editor) published in PubMed-indexed journals. Summarizing, preprints have gained traction as a publishing response to the demand for prompt access to empirical, albeit not peer-reviewed, findings during the present pandemic. Public Library of Science 2020-10-06 /pmc/articles/PMC7537872/ /pubmed/33022014 http://dx.doi.org/10.1371/journal.pone.0240123 Text en © 2020 Gianola et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gianola, Silvia
Jesus, Tiago S.
Bargeri, Silvia
Castellini, Greta
Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic
title Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic
title_full Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic
title_fullStr Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic
title_full_unstemmed Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic
title_short Characteristics of academic publications, preprints, and registered clinical trials on the COVID-19 pandemic
title_sort characteristics of academic publications, preprints, and registered clinical trials on the covid-19 pandemic
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537872/
https://www.ncbi.nlm.nih.gov/pubmed/33022014
http://dx.doi.org/10.1371/journal.pone.0240123
work_keys_str_mv AT gianolasilvia characteristicsofacademicpublicationspreprintsandregisteredclinicaltrialsonthecovid19pandemic
AT jesustiagos characteristicsofacademicpublicationspreprintsandregisteredclinicaltrialsonthecovid19pandemic
AT bargerisilvia characteristicsofacademicpublicationspreprintsandregisteredclinicaltrialsonthecovid19pandemic
AT castellinigreta characteristicsofacademicpublicationspreprintsandregisteredclinicaltrialsonthecovid19pandemic